Objective-Overproduction of intestinally derived apoB-48-containing triglyceride-rich lipoproteins (TRLs) (chylomicrons) has recently been described in type 2 diabetes, as is known for hepatic TRL-apoB-100 (very-low-density lipoprotein) production. Furthermore, insulin acutely inhibits both intestinal and hepatic TRL production, whereas this acute inhibitory effect on very-low-density lipoprotein production is blunted in type 2 diabetes. It is not currently known whether this acute effect on chylomicron production is similarly blunted in humans with type 2 diabetes. Methods and Results-We investigated the effect of acute hyperinsulinemia on TRL metabolism in 18 type 2 diabetic men using stable isotope methodology. Each subject underwent 1 control (saline infusion [SAL]) lipoprotein turnover study followed by a second study, under 1 of the 3 following clamp conditions: (1) hyperinsulinemic-euglycemic, (2) hyperinsulinemic-hyperglycemic, or (3) hyperinsulinemic-euglycemic plus intralipid and heparin. TRL-apoB-48 and TRL-apoB-100 production and clearance rates were not different between SAL and clamp and between the different clamp conditions, except for significantly lower TRL-apoB-100 clearance and production rates in hyperinsulinemiceuglycemic plus intralipid and heparin clamp compared with SAL. Conclusion-This is the first demonstration in individuals with type 2 diabetes that chylomicron production is resistant to the normal acute suppressive effect of insulin. This phenomenon may contribute to the highly prevalent dyslipidemia of type 2 diabetes and potentially to atherosclerosis. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00950209. (Arterioscler Thromb Vasc Biol. 2012;32:1039-1044.)
T he increased risk of atherosclerotic cardiovascular disease associated with insulin-resistant states and type 2 diabetes is of great public health concern. 1 The typical diabetic dyslipidemia is characterized by a number of abnormalities, including elevated plasma triglyceride (TG) levels, low high-density lipoprotein cholesterol, increased proportion of small and dense low-density lipoprotein, and postprandial hyperlipidemia. 2 Dyslipidemia in insulin-resistant states contributes to the residual cardiovascular risk and atherosclerosis. [3] [4] [5] Diabetic dyslipidemia includes characteristic accumulation of triglyceride-rich lipoproteins (TRLs), which has been attributed to a combination of defective TRL removal and overproduction from liver (TRL-apoB-100 or very-low-density lipoprotein [VLDL]) 3 and from intestine (TRL-apoB-48 or chylomicrons). [6] [7] [8] TRL-apoB-48 and TRL-apoB-100 have been identified as proatherogenic in type 2 diabetes. 9 The mechanisms leading to the overproduction of TRLs in the setting of type 2 diabetes and insulin resistance remain to be fully characterized, particularly for intestine. We have recently shown that acute elevation of plasma free fatty acids (FFA) stimulates not only hepatic but also intestinal TRL production in Syrian Golden hamsters 10 and in fed healthy humans, 11 demonstrating functional similarities between these 2 organs in this respect. The effects of hyperglycemia on TRL metabolism remain controversial, either decreasing 12 or stimulating VLDL production. 13 Insulin acutely inhibits hepatic TRL-apoB-100 secretion in healthy humans, in vivo in animals, and in cell culture experiments, [14] [15] [16] [17] [18] [19] even though chronic hyperinsulinemic states, which are usually associated with insulin resistance, are characterized by chronic overproduction of VLDL. In fasting humans, this acute inhibitory effect seems to be completely or partly independent of the FFA suppressive effect of hyperinsulinemia. 16, 18, 19 In insulin-resistant humans and animals, this acute inhibitory effect is blunted or absent. [20] [21] [22] One may speculate that the blunting of this acute suppressive effect may contribute to the chronic overproduction of TRL particles. At the intestinal level, insulin has also been shown to acutely inhibit intestinal TRL-apoB-48 production of the chow-fed hamster but not of the insulin-resistant fructose-fed hamster. 23 Insulin added acutely to the medium of human fetal small intestinal cells reduces chylomicron secretion. 24 More recently, it has been shown, using methodology similar to the present study, that insulin acutely inhibits intestinal lipoprotein secretion in healthy fed humans, in part by suppressing plasma FFA. 25 The acute effect of insulin on intestinal TRL-apoB-48 production has not been previously examined in individuals with type 2 diabetes.
In the present study, we investigated the effects of acute hyperinsulinemia on intestinal and hepatic TRL metabolism in 18 men with type 2 diabetes in a constant fed state under conditions of euglycemia, hyperglycemia, and elevated concentrations of plasma FFA, the latter 2 conditions designed to dissociate the direct or indirect potential effects of insulin.
Methods

Subjects
Mean baseline demographic characteristics and fasting biochemical parameters of the 18 male type 2 diabetic patients are outlined in Table 1 . For details, please see the online-only Data Supplement. The Research Ethics Board of la Méditerranée University approved the study, and all subjects gave written informed consent.
Experimental Protocol for Lipoprotein Kinetic Studies
Each subject underwent 2 separate lipoprotein kinetic studies, as described below, 4 weeks apart. In each study, following an overnight fast, an intravenous catheter was inserted into a superficial vein in each forearm, 1 for infusion and 1 for blood sampling. At 6 am on the day of the kinetic study, the patients started an hourly supplement ingestion (Nutrini Drink, Nutricia, Zoetermeer, the Netherlands: 50% calories from carbohydrates, 9% from proteins, 41% from fat [4.2% of total calories from saturated fat, 24.6% from monounsaturated fat, and 12% from polyunsaturated fat]). From 8 am to the end of the study (10 pm), all patients underwent an initial study with an intravenous infusion of saline (65 mL/h) (SAL). Four weeks later, the subjects were assigned to 1 of 3 hyperinsulinemic clamp conditions, with an attempt to match the 3 groups for age, body mass index, and HbA 1c. The 3 clamp conditions were (1) intravenous infusion of insulin (80 mUI/m 2 ·min Novorapid, Novo Nordisk, Chartres, France) and glucose 20% solution at a variable rate to maintain the blood glucose around 5.5 mmol/L (hyperinsulinemic-euglycemic condition [INS], nϭ6); (2) as in condition 1, but the blood glucose was maintained at approximately 11 mmol/L (hyperinsulinemic-hyperglycemic condition [INSϩGLY], nϭ6); and (3) as in condition 1, but with coinfusion of intralipid (20% solution at 15 mL/h, Fresenius Kabi, Uppsala, Sweden) and heparin (250 U/h, Heparin Choay, Sanofi-Aventis) to prevent the anticipated reduction in circulating FFA that occurs with hyperinsulinemia (hyperinsulinemic-euglycemic plus intralipid and heparin condition [INSϩIH], nϭ6) ( Figure 1A ). For 3 subjects (1 in each treatment group), we used regular human insulin (Actrapid, Novo Nordisk) instead of Novorapid to enable the measurement of plasma exogenous insulin levels throughout the clamps. Blood glucose was assessed at the bedside every 5 to 10 minutes using an Accu-Chek Performa Analyzer (Roche Diagnostics, Meylan, France).
Kinetic studies were performed in a constant fed state because apoB-48 levels are too low in the fasted state to accurately assess isotopic enrichments for calculation of kinetic parameters. To achieve a constant fed state, the subjects ingested aliquots of the liquid food supplement every hour from 6 am to 10 pm, with each hourly aliquot equivalent to 1/16th of their total daily caloric needs as estimated by the use of the Harris-Benedict equation (mean caloric intakeϮSEM: 1806Ϯ15 kcal). Four hours after starting to ingest the liquid formula and 2 hours after starting infusions of saline, insulin, or insulin plus intralipid and heparin (at 10 am), subjects received a primed-constant infusion (10 mol/kg bolus followed by 10 mol·kg Ϫ1 ·hr Ϫ1 for 12 hours) of deuterium-labeled leucine (l-[5,5,5-2 H 3 ]-leucine, 99%, Cambridge Isotope Laboratories, Andover, MA) to enrich apoB-48 and apoB-100 for assessment of the fractional catabolic rate (FCR), the pool size (PS), and the production rate (PR) of TRL-apoB-48 and TRL-apoB-100 as previously described. 7 Blood samples were collected in the fasting state (6 am), before (10 am) and after the start of the primed-constant infusion of D3-leucine, at 1, 3, 5, 7, 9, 10, 11, and 12 hours.
Laboratory Methods
Plasma was immediately separated from blood samples at 3500 rpm for 15 minutes at 4°C. TRLs were isolated by gradient ultracentrifugation as previously described. 26 Proteins in the TRL fraction were determined, 27 delipidated, and subsequently separated by SDS-PAGE, with clear separation of the apoB-48 and apoB-100 bands. apoB-48 and apoB-100 gel slices were hydrolyzed and derivatized to allow the determination of leucine isotopic enrichment, as previously described, 7 by electron impact ionization gas chromatography/mass spectrometry. Tracer-to-tracee ratios were calculated from isotopic ratios for each sample and standard enrichment curves. For details, please see the Methods section in the online-only Data Supplement. corrected in relation to weight). 28 For details, please see the Methods section in the online-only Data Supplement. TRL-apoB-48 and TRL-apoB-100 tracer-to-tracee ratios versus time are presented in Figure IIA to IID in the online-only Data Supplement.
Calculation of Lipoprotein PS and Production and Clearance Rates by Compartmental Modeling
Statistical Analysis
Statistical analysis was performed using SPSS (version 17.0, SPSS, Chicago, IL) software. Results are presented as meansϮSEM. The mean values of the parameters and the statistical comparison between studies were calculated during the 12-hour kinetic studies (ie, from 10 am to 10 pm, the time period of deuterated leucine infusion). The Wilcoxon paired test was used to study changes between SAL and clamp conditions, and the Kruskal-Wallis test was used for comparisons among the 3 groups in the SAL condition and in clamp conditions. For all the analyses, PϽ0.05 was considered significant.
Results
Fasting Plasma Lipids, Biochemical Characteristics, and TRL Composition of Patients
At baseline (fasting state of the SAL condition), the 3 treatment groups (INS, INSϩGLY, and INSϩIH) were well matched, with no significant difference in demographic characteristics or fasting biochemical parameters ( Table 1) . Figure 1B-1D ). Plasma C-peptide and glucose infusion rate were higher in INSϩGLY compared with INS or INSϩIH (PϽ0.01 for both). There were no differences in plasma TG, TRL-TG, TRL-apoB-48, and TRL-apoB-100 levels among the 3 groups. For details, please see Table I and Figure IIIA to IIID in the online-only Data Supplement.
Concentrations of TG, FFA, Insulin, C-Peptide, and Glucose in Plasma and of TG, apoB-48, and apoB-100 in TRL Fraction
When we compared SAL and clamp conditions within each treatment group (INS, INSϩIH or INSϩGLY), we found in INS that plasma glucose and C-peptide concentrations decreased significantly in clamp versus SAL (PϽ0.01 for both), whereas plasma FFA, plasma TG, TRL-TG, TRL-apoB-48, and TRL-apoB-100 concentrations did not change significantly. In INSϩGLY, TRL-TG, TRL-apoB-48, and TRL-apoB-100 concentrations decreased significantly in clamp versus SAL (PϽ0.05 for all), whereas plasma glucose, TG, FFA, and C-peptide concentrations did not change significantly. In INSϩIH, plasma glucose and C-peptide concentrations decreased significantly, whereas plasma FFA increased significantly in clamp versus SAL (PϽ0.01 for all) and plasma TG, TRL-TG, TRL-apoB-48 and TRL-apoB-100 concentrations did not change significantly. For details, please see Table I and Figure IIIA to IIID in the online-only Data Supplement.
Effect of Acute Hyperinsulinemia on TRL-apoB-48 and TRL-apoB-100 PS, FCR, and PR
There were no differences in TRL-apoB-48 or TRL-apoB-100 PS, FCR, and PR between SAL and clamp conditions for 
Discussion
We have shown for the first time in humans that the acute inhibitory effect of insulin on intestinal TRL-apoB-48 production, recently shown in healthy humans using a similar method, 25 is blunted in patients with type 2 diabetes. Our findings are in keeping with the results of an animal study showing that intestinal lipoprotein production of chow-fed hamsters but not insulin-resistant fructose-fed hamsters was responsive to the acute inhibitory effect of insulin. 23 The intestinal insulin insensitivity is accompanied by impaired insulin signaling that has been shown ex vivo in enterocytes of fructose-fed hamsters. 23 The consequences of the insulin signaling defect at the level of the enterocyte are an increase in de novo lipogenesis and chylomicron assembly and secretion. 23, 29, 30 We also confirmed the results of several studies in animal models of insulin resistance 22, 31, 32 in type 2 diabetic 20 and obese, insulin-resistant human subjects, 21 showing that the acute inhibitory effect of insulin on hepatic TRL-apoB-100 production is blunted.
The kinetic parameters of our study are different (lower PS and PR and higher FCR) with regard to those of the only kinetic study on TRL-apoB-48 metabolism in type 2 diabetic subjects versus controls, 8 but several differences between the 2 studies may explain these discrepancies. The diabetic population in that study was more insulin resistant (mean HOMA-IR: 5.6 versus 4.4) and was frankly more hypertriglyceridemic (mean fasting plasma TG levels: 4.6 versus 2.0 mmol/L) than our diabetic population. The diet was solid and ingested every half-hour versus liquid and hourly in our study. TRL-apoB-48 levels were measured using analytic SDS-PAGE versus ELISA in our study. To calculate the PS, we corrected the plasma volume in relation to weight. Oral hypoglycemic drugs were only metformin, sulfonylurea, or both in our study, but 3 patients received a thiazolidinedione in the other study, and the majority of our patients received lipid-lowering drugs. We found no difference in the kinetic parameters of TRL-apoB-48 and TRL-apoB-100 between SAL and clamp regardless of their lipid-lowering therapy (statin, fibrate, or no treatment) but a significant increase in TRL-apoB-100 PR in the fibrate group in SAL (Table IV in the online-only Data Supplement). Our study was not designed to assess the effect of lipid-lowering drugs. Those treated with the various lipid-modifying agents were distributed equally among the 3 groups, the medications were continued unchanged throughout the study, and each subject served as his own control. Although we cannot completely rule out a potential confounding effect of these drugs on the main findings of the present study, it is unlikely that the absence of insulin-mediated suppression of TRL-apoB-48 or apoB-100 production would have occurred as a result of the fact that the patients enrolled in the present study were taking lipid-lowering therapies. An acute elevation of plasma FFA has previously been shown to stimulate TRL-apoB-48 production in healthy humans 11 and in chow-fed hamsters, 10 with no stimulatory effect of FFA seen in insulin-resistant hamsters that already overproduce TRL-apoB-48. 10 These findings are in keeping with our observation, in that a marked elevation of plasma FFA in the clamp-INSϩIH study failed to significantly stimulate TRL-apoB-48 PR compared with SAL, although there was a nonsignificant trend toward an increase in TRL-apoB-48 PR. FFA may stimulate intestinal TRL-apoB-48 assembly and secretion by impairing insulin signaling or by increasing the pool of intracellular fatty acids incorporated into secreted lipoprotein particles. 33 In the present study, we obtained no efficient additive suppression of plasma FFA under any of our clamp conditions compared with SAL, which could partly explain the inability of insulin to acutely suppress TRL-apoB-48 production. Impaired clearance of intestinal TRL-apoB-48 and hepatic TRL-apoB-100 has been shown in patients with type 2 diabetes compared with controls, 8 possibly related to the postprandial impairment of lipoprotein lipase stimulation that normally occurs in nondiabetic subjects. 34, 35 In our study and similar studies in healthy humans, there was no clear acute impairment in TRL-apoB-48 FCR when insulin or FFA concentrations were experimentally raised. 11, 25 The INSϩIH group showed a parallel decrease of FCR and PR of hepatic TRL-apoB-100 without any change in the PS in clamp versus SAL. The reduction of FCR could be explained by the impeded effect of intralipid infusion on normal lipoprotein lipase-mediated lipolysis reflecting the competition between intralipid (chylomicron-like TRLs) and VLDL for the same lipolytic pathway, previously described in healthy young men, 36 or by the reduction in TRL-apoB-100 PR decreasing substrate for lipoprotein lipase-mediated lipolysis. The acute role of plasma FFA in the TRL-apoB-100 production is still being debated. Whereas it has been reported that acute elevation of plasma FFA stimulates TRL-apoB-100 production in healthy fasted and fed humans, 11, 16 the similar increase of plasma FFA (2-fold) by heparin infusion did not lead to a rise in VLDL production in the same population. 37 Moreover, the reduction of plasma FFA with acipimox decreased the PR of VLDL1, increased the PR of VLDL2 fraction, and produced no change in total VLDL PR. 18 The explanation could be that FFA availability regulates the production of VLDL in the longer term but not acutely because the use of cytosolic TGs, rather than plasma FFA, as a direct source of VLDL provides a buffer mechanism. 37 The reduction of TRL-apoB-100 FCR in INSϩIH could reduce the TRL-TG source taken up by the liver and directly available for VLDL production and may explain the decrease of TRL-apoB-100 PR. Recently, it has been shown in vivo (McA-RH7777 cells) and in vivo in mice, a parabolic effect on apoB-100 secretion, with moderate FFA exposure increasing apoB-100 secretion, whereas greater lipid loading inhibited apoB-100 in a duration-dependent manner (the incubation of McA-RH7777 cells for 16 hours with 100 mg/dL intralipid stimulated apoB-100 secretion, whereas 500 mg/dL inhibited it and had no effect on apoB-48 secretion). This decrease effect was linked to the induction of endoplasmic reticulum stress increasing apoB-100 degradation through both proteasomal and nonproteasomal pathways, worsening hepatic steatosis. 38 We also showed that acute elevation of blood glucose together with hyperinsulinemia did not affect TRL-apoB-48 or TRL-apoB-100 FCR or PR. However, we found in INSϩGLY a significant decrease in TRL-apoB-48 PS in clamp versus SAL. This decrease in TRL-apoB-48 PS could be due to a tendency toward an increase in TRL-apoB-48 FCR, a decrease in TRL-apoB-48 PR that associated with a tendency to an increase in TRL-apoB-100 FCR (ϩ30%) could explain the significant decrease of TRL-apoB-48, TRL-apoB-100, and TRL-TG in INSϩGLY. The role of glucose on TRL metabolism remains debated. In a short-term (not acute) study, a reduction in postprandial chylomicrons has been shown after the improvement of glycemic control in type 2 diabetes using intensified dietary intervention, drugs, or insulin. 39 Whereas VLDL-TG was shown to be decreased in lean men and women and in obese men but not obese women in hyperinsulinemic-hyperglycemic conditions, 12 another study has found that hyperglycemia is a driving force in the overproduction of VLDL1 but not VLDL2 in type 2 diabetes. 13 Both studies were conducted in a fasting state. 12, 13 In a study with a design similar to the present study except performed in the fasting state and with a shorter duration of the hyperinsulinemic clamp in type 2 diabetes, VLDL1 and VLDL2 PR and FCR were comparable regardless of euglycemic or hyperglycemic conditions, except a significant reduction in VLDL2 PR under hyperglycemic compared with saline conditions. 20 Two human studies have recently shown improvement in postprandial lipemia after acute intravenous administration of glucagon-like peptide 1 in healthy subjects 40 or after 4 weeks of treatment with a dipeptidyl peptidase IV inhibitor in patients with type 2 diabetes. 41 In our study, C-peptide was not effectively suppressed in INSϩGLY during hyperinsulinemic clamp, but we are not able to dissociate the role of hyperglycemia or the glucosedependent insulinotropic effect of glucagon-like peptide 1 on this endogenous insulin secretion in our constant-fed condition.
In conclusion, the present report has extended previous findings in animal models of insulin resistance to humans with type 2 diabetes and also from the liver to the intestine, demonstrating that the acute inhibitory effect of insulin on intestinal TRL-apoB-48 production is absent in patients with type 2 diabetes. We speculate that the absence of additive insulin-mediated suppression of plasma FFA in these patients may have partly accounted for this lack of insulin-mediated suppression of TRL-apo-B48 secretion, but we found in parallel an acute inhibitory effect of high plasma FFA levels on hepatic TRL-apoB-100 production. This resistance to insulin's acute suppressive effect on both intestinal TRL-apoB-48 (shown in this report) and hepatic TRL-apoB-100 (shown by others previously [20] [21] [22] ) production in type 2 diabetes may contribute to the highly prevalent dyslipidemia of type 2 diabetes and potentially to atherosclerosis.
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